Multi-center Phase IbII Study of YL202 Combined With Toripalimab or Furmonertinib for Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of YL202 combined with other anti-tumor therapies in patients with advanced solid tumors. This multi-center, open-label phase IbII study focuses on patients with conditions such as advanced solid tumors, breast cancer, and non-small cell lung cancer, aiming to understand how these combinations work together in treating these cancers. The study has multiple parts Parts 1 and 3 involve YL202 given intravenously with Toripalimab injection, including dose escalation and expansion stages where doses are adjusted and optimized. Parts 2 and 4 include YL202 intravenously combined with oral Furmonertinib Mesilate tablets, also in dose escalation and expansion phases. Participants receive escalating doses of YL202 alongside fixed doses of the other drugs to determine the best treatment levels. Participants will undergo monitoring for dose-limiting toxicities within 21 days after the first dose and adverse events for 42 days after treatment ends. The study also tracks tumor response, drug pharmacokinetics, and immune reactions for up to about three years. Throughout the trial, patients will have regular visits for assessments, tumor evaluations, and safety checks to understand treatment effects and tolerability over time.

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors